Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
Joseph M. Gozgit, Rachel M. Squillace…Volume:
71
Language:
english
DOI:
10.1007/s00280-013-2131-z
Date:
May, 2013
File:
PDF, 626 KB
english, 2013